2026 China GCP: New Clinical Trial PV Requirements for Overseas MAHs
Learn how China's 2026 revised GCP changes clinical trial pharmacovigilance requirements for overseas MAHs, including SUSAR reporting, PI responsibilities, PV oversight, and CRO compliance.
2026 China GCP Takes Effect: A Major Shift in Clinical Trial Pharmacovigilance Compliance for Overseas MAHs
China's revised Good Clinical Practice (GCP) framework officially took effect on 1 September 2026, introducing significant changes to the way pharmacovigilance (PV), safety reporting, risk management, and responsibilities are managed during clinical trials in China.
On 1 September 2026, the revised Good Clinical Practice for Pharmaceutical Products (2026 Revision), issued under NMPA Announcement No. 50 of 2026, came into force, replacing the 2020 GCP framework.
The revision represents more than a restructuring or reduction in the number of provisions.
Although the new GCP contains fewer provisions than the previous version, it introduces or restructures several important requirements related to clinical trial safety management, risk control, safety reporting, investigator responsibilities, data traceability, and oversight of outsourced activities.
For overseas Marketing Authorization Holders (MAHs) and international sponsors conducting clinical trials in China, this creates an important compliance priority:
Existing clinical trial PV processes should be reviewed against the 2026 GCP requirements rather than assumed to remain fully adequate.
Below are eight areas that deserve particular attention.
1. From Reactive Reporting to Proactive Risk Management
One of the most important themes in the revised framework is the stronger emphasis on risk management throughout the clinical trial lifecycle.
The revised GCP introduces the concept of Quality by Design (QbD) into clinical trial quality management and places greater emphasis on identifying and controlling risks proactively.
What does this mean for overseas MAHs?
Historically, some clinical trial teams have operated primarily around a reactive model:
SAE/SUSAR occurs → assess → report → document
Under the evolving regulatory environment, this approach may no longer be sufficient.
Sponsors should be able to demonstrate:
How safety risks were identified
How risks were assessed and categorized
What mitigation measures were implemented
Who was responsible for risk decisions
How risk controls were monitored
How decisions and actions were documented
The key shift is from simply demonstrating that an event was reported to demonstrating that clinical trial risks were actively identified, assessed, controlled, and documented throughout the study.
For overseas MAHs, this means that the China PV framework should be integrated into the broader clinical trial quality management system rather than operated as a standalone reporting function.
2. SUSAR Ethics Review: A More Risk-Based Approach
The revised GCP introduces a more differentiated approach to ethics review of SUSARs.
Rather than applying exactly the same expedited ethics review process to every SUSAR, the review approach should reflect the urgency of the risk and changes in the safety profile of the investigational product.
This creates an important operational challenge for multinational sponsors.
Different clinical trial sites may have different operational requirements for ethics submissions.
Therefore, sponsors should establish clear processes for:
SUSAR classification
Risk assessment
Ethics submission pathways
Submission timelines
Documentation
Decision-making responsibility
Evidence of the rationale for the selected pathway
For multicentre studies, simply having a global SUSAR SOP may not be sufficient.
Sponsors should also understand how the process is implemented at individual Chinese sites.
3. SAE Reporting Responsibilities: Review PI and CRC Roles
The revised GCP places increased emphasis on the investigator's responsibility for formal SAE reporting.
According to the source article, the revised framework limits delegation of formal SAE reporting and places responsibility for formal reporting, confirmation, and decision-making with the Principal Investigator (PI). CRCs may support activities such as information collection and system entry but should not replace the PI in formal sign-off.
This is particularly important for international sponsors because CRCs often provide substantial operational support during clinical trials in China.
Sponsors should therefore review:
Investigator delegation logs
SAE reporting SOPs
PI responsibilities
CRC responsibilities
Electronic reporting workflows
Signature and approval processes
Training records
Any workflow that does not clearly distinguish administrative support from investigator responsibility should be reassessed.
4. SAE Reporting to Both the Sponsor and Ethics Committee
Another important change highlighted in the source article is the strengthening of the PI's reporting obligations.
The revised framework requires PI reporting of SAE information to both the sponsor and the ethics committee, creating a dual reporting pathway.
This introduces a practical data integrity challenge.
For example:
Sponsor receives SAE information → Ethics Committee receives SAE information
The information provided to both parties should remain appropriately consistent and traceable.
Sponsors should consider implementing reconciliation controls covering:
Case identification
Event information
Dates
Seriousness criteria
Causality assessment
Outcome
Follow-up information
Subsequent modifications
Where information is updated, the change should be appropriately documented and traceable.
For multinational clinical trials, this is particularly important where the global safety database and China-specific reporting processes operate through different systems.
5. The PI's Role Is Evolving from Administrative Sign-Off to Active Medical Oversight
The revised framework also places greater emphasis on the PI's independent medical responsibilities.
The source article highlights the removal of certain previous requirements relating to PI-mediated SUSAR transmission and emphasizes the PI's responsibility to:
Review safety information promptly
Independently assess treatment-related risks
Communicate appropriately with subjects
Maintain documentation of medical assessments and communications
This represents an important shift in the practical interpretation of investigator responsibilities.
A PI should not simply be viewed as the person who receives and signs safety documentation.
Sponsors should be able to demonstrate that relevant medical decisions and risk assessments were actually performed and appropriately documented.
6. SUSAR Reporting: CDE as the Central Regulatory Reporting Pathway
The revised framework also restructures the regulatory reporting pathway for SUSARs and serious safety information.
The source article identifies the Center for Drug Evaluation (CDE) as the central regulatory reporting destination and emphasizes that changes to reporting pathways should not be interpreted as elimination of statutory reporting obligations.
This is an important point for overseas MAHs.
A risk-based or differentiated reporting process does not automatically mean that a safety event is exempt from regulatory reporting.
Sponsors should maintain clearly documented:
Reporting criteria
Risk classification methodology
Decision-making responsibilities
Reporting pathways
Reporting timelines
Supporting documentation
Audit trails
A written and traceable decision-making process is particularly important during regulatory inspection.
7. CRO, SMO and PV Vendors Remain Within the Sponsor's Compliance Framework
Another major area of concern is outsourcing.
The revised framework emphasizes that requirements applicable to sponsors also extend to relevant outsourced service providers, including CROs, SMOs and PV service providers.
For overseas MAHs, this is highly relevant.
Many international sponsors outsource most or all China clinical PV activities to local service providers.
However:
Outsourcing an activity does not eliminate the sponsor's need for oversight.
Sponsors should therefore evaluate whether their outsourced partners have:
Appropriate SOPs
Qualified personnel
Adequate training
Effective reporting processes
Complete documentation
Appropriate escalation mechanisms
Effective quality management systems
Adequate audit trails
Vendor qualification alone is not enough.
Ongoing oversight and periodic audit should form part of the sponsor's China PV governance framework.
8. PV Oversight Extends Beyond Individual SUSAR Cases
One of the most significant themes highlighted by the revised framework is the broader concept of potential serious safety risks.
The source article highlights an expanded focus beyond individual SUSAR cases to include potential aggregate safety signals and other information that may affect the benefit-risk profile or clinical development process. It also emphasizes traceability of safety data modifications, metadata retention, and audit trails.
This means that sponsors should not focus exclusively on:
"Did we report every SUSAR?"
They should also ask:
"Can we demonstrate that we continuously monitor, evaluate, document and escalate emerging safety risks?"
This requires an effective signal detection and risk evaluation process supported by appropriate documentation and data traceability.
What Does the 2026 GCP Mean for Overseas MAHs?
The overall message is clear:
Fewer provisions do not necessarily mean lower regulatory expectations.
The revised framework changes the way responsibilities, risk management, reporting pathways and outsourced activities are structured.
The source article summarizes the new model as moving toward:
Overseas MAH / Sponsor → direct oversight of relevant stakeholders
PI → independent medical risk responsibility
CDE → centralized regulatory reporting pathway
CRO / SMO / PV vendors → subject to effective sponsor oversight
For overseas MAHs, this means that existing China clinical PV arrangements should be systematically reassessed.
What Should Overseas MAHs Review Now?
We recommend conducting a structured China Clinical PV Compliance Gap Assessment covering at least the following areas:
1. PV SOPs
Review whether existing China-specific procedures remain aligned with the 2026 GCP framework.
2. SAE/SUSAR Reporting Workflows
Confirm reporting responsibilities, timelines, approval mechanisms and documentation requirements.
3. PI and CRC Responsibilities
Review delegation matrices and ensure that formal investigator responsibilities are clearly distinguished from CRC administrative support.
4. Ethics Submission Processes
Assess whether SUSAR classification and ethics submission procedures are appropriate for different levels of safety risk.
5. Risk Management
Evaluate whether safety risks are identified and controlled proactively rather than only addressed after an event occurs.
6. Data Traceability
Verify that safety information can be traced across relevant systems, documents and reporting pathways.
7. CRO/SMO/PV Vendor Oversight
Review vendor qualification, quality agreements, SOPs, training, performance monitoring and audit arrangements.
8. Audit and Inspection Readiness
Assess whether the China clinical PV system can provide sufficient evidence of compliance during an NMPA inspection.
How PV Solutions Supports Overseas MAHs
At PV Solutions Limited, we specialize in helping international pharmaceutical companies navigate China's evolving regulatory and pharmacovigilance requirements.
For the 2026 GCP transition, our China clinical PV compliance support can include:
China Clinical PV Compliance Audits
We assess existing clinical trial PV processes against applicable Chinese regulatory requirements, identifying gaps in:
Safety reporting
Documentation
SOPs
Risk management
Data traceability
Ethics submission processes
Investigator responsibilities
PV Process and SOP Gap Assessment
We review existing global and China-specific procedures and identify areas requiring localization or revision.
SUSAR Reporting Process Review
We assess reporting workflows, decision-making criteria, documentation and communication between:
Sponsor ↔ PI ↔ Ethics Committee ↔ CDE
CRO / SMO / PV Vendor Compliance Audits
We evaluate whether outsourced service providers are operating in accordance with their contractual and regulatory responsibilities.
PI / CRC / PV Training
We provide targeted training on:
2026 GCP requirements
SAE/SUSAR responsibilities
Reporting pathways
Documentation and traceability
Risk management
Inspection expectations
Inspection Readiness
We help sponsors identify potential findings before an NMPA inspection and develop practical remediation plans.
Don't Wait for an Inspection to Identify the Gap
For international sponsors, the most significant risk is not necessarily the existence of a regulatory change.
It is assuming that an existing China PV system remains compliant simply because it was compliant under the previous framework.
The 2026 GCP provides an important opportunity for overseas MAHs to reassess their China clinical trial governance, strengthen local oversight and ensure that responsibilities between sponsors, investigators, ethics committees and outsourced service providers are clearly defined.
A proactive compliance gap assessment is significantly more valuable than discovering a system weakness during an inspection.
Conclusion
China's 2026 GCP represents an important development in the country's clinical trial regulatory framework.
For overseas MAHs, the key challenge is translating the revised requirements into practical, documented and auditable processes.
The priority should not simply be:
"Have we updated our SOP?"
Instead, sponsors should ask:
"Can we demonstrate that our China clinical PV system works in practice?"
That means ensuring that safety information is appropriately identified, assessed, reported, documented and traceable—and that every party involved understands its responsibilities.
At PV Solutions Limited, we support international pharmaceutical and biotechnology companies in strengthening China clinical PV compliance, preparing for regulatory inspections, and adapting global quality systems to China's local regulatory environment.
If your organization is conducting clinical trials in China, now is the right time to assess whether your existing clinical PV framework is ready for the 2026 GCP requirements. Contact us for your request.
References
Good Clinical Practice for Pharmaceutical Products (2026 Revision) — NMPA Announcement No. 50 of 2026
Key Points and Determination Principles for Drug Registration Inspection (Drug Clinical Trials) (Trial Implementation)
Applicable Chinese clinical trial pharmacovigilance and safety reporting requirements
The uploaded source identifies the revised GCP as effective from 1 September 2026 and specifically highlights changes relating to QbD, SUSAR ethics review, SAE reporting, PI responsibilities, CDE reporting, outsourced service providers and aggregate safety signals.